🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

21 recruiting trials

for Mild to Moderate Dementia

Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease NCT05924425Phase 41 site📍 Montpellier University Hospital, Montpellier · Tests: Daridorexant 50 mg, Placebo, Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural pr… An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease NCT05908695Phase 450 sites📍 Huainan📍 Beijing📍 Beijing Green Valley (Shanghai) Pharmaceuticals Co., Ltd. · Tests: GV-971, Placebo A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) NCT07633470Phase 422 sites📍 Irvine📍 Orange📍 Aventura Alpha Cognition, Inc · Tests: Zunveyl® Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease NCT05295615NA1 site📍 Hackensack Herrick Medical LLC · Tests: ECHS AD Device The Feasibility and the Efficacy of the Full-immersive Virtual Reality Cognitive Training in Patients With Mild or Moderate Dementia NCT07033468NA1 site📍 New Taipei City Chang Gung Memorial Hospital · Tests: VR-WLC, CTL-VR Pulsed Electromagnetic Field Treatment With Dementia Patients NCT06862557NA1 site📍 Boca Raton Herrick Medical LLC · Tests: ECHS AD Device Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease NCT07869238NA1 site📍 Seoul Neumous Inc. · Tests: NMS-01 Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type NCT07066826Phase 2, Phase 31 site📍 Beijing Wanbangde Pharmaceutical Group Co., LTD · Tests: Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets, Huperzine A controlled-release tablets placebo… A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease NCT06702124Phase 31 site📍 Rome I.R.C.C.S. Fondazione Santa Lucia · Tests: Rotigotine 4Mg/24Hrs Patch, Placebo A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) NCT06976203Phase 3128 sites📍 Fullerton📍 Irvine📍 Los Angeles Bristol-Myers Squibb · Tests: KarXT, KarX-EC, Placebo A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease NCT06995573Phase 1, Phase 210 sites📍 Salzburg📍 Graz📍 Innsbruck NSC-Therapeutics · Tests: NSC001, Placebo Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease NCT05926011NA7 sites📍 Castres📍 Lavaur📍 Paris REGEnLIFE SAS · Tests: RGn600, RGn600 Sham CST+MST Intervention on People Living With Mild-to-moderate Dementia NCT07625241NA1 site📍 Genova Istituto Superiore di Sanità · Tests: Cognitive Stimulation Therapy and Motor Stimulation Treatment A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease NCT06976216Phase 3119 sites📍 Long Beach📍 Redlands📍 Basalt Bristol-Myers Squibb · Tests: KarXT, KarX-EC, Placebo Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia NCT04957537NA1 site📍 Toulouse University Hospital, Toulouse · Tests: semantic therapy and semantic re-education Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD) NCT06597942Phase 1, Phase 21 site📍 Los Angeles University of California, Los Angeles · Tests: TMS, Transcranial Magnetic Stimulation Sham Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney) NCT06534723Phase 31 site📍 Fuzhou Sichuan Jishengtang Pharmaceutical Co., Ltd. · Tests: Wujia Yizhi granules, Placebo Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD) NCT04124029n/a1 site📍 Boston VA Office of Research and Development · Tests: No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing an… Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia NCT06584357n/a26 sites📍 Atlantis📍 Aventura📍 Clermont GAP Innovations, PBC · Tests: Biomarker Data Collection, MK6240 Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease NCT07367815Phase 1, Phase 21 site📍 Toulouse University Hospital, Toulouse · Tests: CellREADY® drug product IV dose of 50 millions, CellREADY® drug product IV dose of 100 millions, cerebral RMI, PET scan Dyadic Personalized Home-Based Activity Program for Mild-to-Moderate Dementia Patients Post-Discharge NCT07081750NA1 site📍 Fujian Fujian Medical University · Tests: Dyadic personalized home-based activity program intervention, Routine care
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy